Shares follow today on the Paris Stock Exchange – Thursday 7 April 2022

(AOF) – Abivax

Good news for Abivax. The company on Wednesday evening announced excellent efficacy and safety results after one year of treatment in the Phase 2b maintenance study of ABX464 in ulcerative colitis. “Final preparations for the international Phase 3 clinical program with ABX464 at UC are underway, with first patient enrollment planned for Q3 2022,” added Abivax.

Akwell

The automotive supplier will publish its annual results.

BIO UV

BIO-UV announced pro forma net income – through integration of Corelec over 12 months – of €3.3 million for 2021. On a pro forma basis, the new entity’s 2021 Ebitda was EUR 7.5 million, representing an Ebitda margin of 16.8%. On the same basis, the turnover of the specialist for water treatment and disinfection systems reached 44.4 million euros, which reflects the change in size implemented at the end of the financial year.

DeltaDrone

As announced in the press release dated March 31, 2022, Delta Drone made the announcement of the reverse stock split in its legal bulletin – Bulletin #41 dated April 6, 2022 – on Wednesday. The announcement published in BALO describes in detail the characteristics of the operation, which will begin on April 22nd and end on May 23rd. The consolidation basis corresponds to the exchange of 10,000 old shares with a nominal value of EUR 0.0001 for 1 new share with a nominal value of EUR 1.

Erytech

Erytech announced the publication of positive results from the phase 2 study evaluating eryaspase in hypersensitive ALL in the British Journal of Haematology. The study confirms eryaspase (GRASPA) as an interesting therapeutic option for patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to pegylated asparaginase.

Fleury Michon

Fleury Michon made a profit of 4 million euros in 2021 after registering a loss of 30.5 million the previous year. The agri-food group also reported a current operating margin of 2%, compared to 2.6% in 2020, marked by operating profits reinvested to support the Fleury Michon brand. Revenue, for its part, posted a 4.1% decline, impacted by GMS activity, whose revenue fell by 4.2% compared to the previous fiscal year, due to the impact of the March-May 2020 lockdown.

genefit

The biopharmaceutical company will publish its annual results.

Hipay

In 2021, Hipay recorded a net loss of 4.3 million euros compared to 1.8 million in 2020. The company was penalized with the “full and prudent provision for a tax risk”. The payment service provider’s EBITDA reached 2.8 million euros, positive for the second year in a row, after + 3.4 million euros in 2020, the year in which the company had benefited from cost savings related to operational costs related to the healthcare context , in particular sub-activities Measures 2021 not extended. Adjusted for this effect, the EBITDA shows an increase of 88%.

CDL

The poultry farmer publishes his annual turnover.

Onxeo

Onxeo has approved the appointment of Dr. Shefali Agarwal announced as CEO. dr Agarwal succeeds Julien Miara, Director at Invus SAS, who was appointed interim CEO in January 2022. “In her role as CEO, I worked closely with Dr. Agarwal to further develop our company, strengthen our board and, most importantly, develop our product portfolio,” commented Julien Miara.

Sanofi

The European Commission (EC) has extended marketing authorization for Sanofi’s Dupixent (dupilumab) in the European Union. Dupixent is now approved for the adjunctive disease-modifying treatment of severe asthma associated with type 2 inflammation characterized by increased blood eosinophils and/or increased fractional exhaled nitric oxide (FeNO) in children aged 6 to 11 years who are inadequately controlled by medium- to high-dose inhaled corticosteroids in combination with other disease-modifying asthma therapy.

Sopra Steria

Sopra Steria reaffirms its commitment to the fight against climate change by announcing the inclusion of an extra-financial indicator structured by Crédit Agricole CIB and LCL in the refinancing conditions of its €1.1 billion syndicated credit line.

Voltalia

Voltalia has won its first floating solar power plant project in Portugal with a total capacity of at least 33 megawatts, backed by a 15-year power purchase agreement. This project, called “Cabril”, was won after a tender organized by the Portuguese Ministry of Energy and Environment. This new floating solar power plant will be installed near the Cabril dam in Sertã.

Leave a Comment